Orbus Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
7
Active:4
Completed:0
Trial Phases
2 Phases
Phase 1:5
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (71.4%)Phase 3
2 (28.6%)Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Phase 1
Recruiting
- Conditions
- Glioblastoma, IDH-wildtypeGlioblastomaGlioblastoma MultiformeGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeGBMAstrocytomaAstrocytoma, IDH-Mutant
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Orbus Therapeutics, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT05879367
- Locations
- 🇺🇸
Brown University Health/Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Phase 3
- Conditions
- Anaplastic AstrocytomaRecurrent Anaplastic Astrocytoma
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Orbus Therapeutics, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT02796261
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Kaiser Permanente, Sacramento, California, United States
News
No news found